Health
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial – The Lancet
Dabrafenib plus trametinib combination treatment showed promising activity in patients
with BRAFV600E-mutated biliary tract cancer, with a manageable safety profile. Routine
testing for BRAFV600E mutations should be considered in patients with biliary tract
c…
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions…
Continue Reading